Briviact from UCB S.A. - fast-acting add-on for hard-to-treat seizures

Reviewed: ad hoc news New Release & Launch desk. Edited and checked on 2026-06-30, 03:00. Details in the imprint.

Briviact sits in a small white blister pack on the kitchen table, the tablet almost unimposing until you remember the last nocturnal seizure. The name Briviact is now part of the morning routine, squeezed between coffee, pill organizer and a quiet glance at the clock. For many families, it marks the moment they try one more targeted add-on therapy.

What Briviact is made for

Briviact from UCB S.A. is an oral antiepileptic designed as an adjunctive therapy for partial-onset seizures in patients who do not gain sufficient control from drugs like levetiracetam. It is built around the active substance brivaracetam, a high-affinity ligand of the synaptic vesicle protein 2A, which is thought to help stabilize neuronal firing in the brain. Compared with broad-acting older medicines, Briviact focuses on a very specific binding profile, which neurologists value when fine-tuning complex treatment plans.

UCB, long known in neurology circles for levetiracetam, positioned Briviact to sit one step further along the treatment path, often when baseline seizure control exists but occasional breakthrough episodes remain. In practice, that means Briviact is rarely the first pill a patient receives after a diagnosis. Instead, it arrives when the neurologist writes a line like "adjunctive therapy with Briviact" into the chart, looking for additional stability without completely rewiring a regimen that otherwise works tolerably well.

How a dose feels in daily life

Ask neurologist Dr. Marie Lambert in Brussels, and she will describe a very concrete scene: a teenager sliding a Briviact tablet from the foil, small enough to swallow with a sip of water, without the chalky aftertaste that older antiepileptics often carried. The pill is smooth to the touch, with a tidy break line on certain strengths that makes dose adjustment more manageable. For the patient, the sensation is almost uneventful, which is precisely what Lambert likes; the medicine should feel like a controlled habit, not a daily struggle.

Parents, meanwhile, often report the sound of the blister cracking becoming a sort of checkpoint in the day. It is not dramatic. It is a quiet click at breakfast or dinner, a reminder that seizure risk is being managed. Briviact's dosing schedule tends to be twice daily, which fits reasonably well with standard routines built around meals. The practical side matters: a treatment that slides into the rhythm of the household stands a better chance of long-term adherence than one that demands irregular, disruptive dosing.

Dosing, formulations and flexibility

Briviact is typically available in multiple oral strengths, allowing physicians to start at a lower dose and adjust upward based on response and tolerability. In many markets, that includes film-coated tablets and oral solution formats. The tablets are designed to be swallowed whole and offer a clear numeric imprint, which reduces the risk of confusion when several medications line a patient's weekly pill box. Such design details may seem minor, but for patients juggling three or more neurological drugs they lower the cognitive load of treatment.

For clinicians, flexibility lies at the core of Briviact's role. If a patient on levetiracetam still experiences focal seizures, adding Briviact rather than switching entirely can help test whether seizures respond to a more selective SV2A interaction. This approach allows maintenance of an established baseline while exploring incremental control. It also gives physicians room to adjust brivaracetam dosage stepwise, instead of committing immediately to a high dose that might bring tolerability issues.

Why neurologists reach for it

UCB's chief executive officer Jean-Christophe Tellier often emphasizes that the firm's neurology portfolio is built around long-term relationships with specialist physicians, not one-off product launches. Briviact fits this philosophy: it is not marketed as a magic bullet, but as an additional lever in the neurologist's toolkit. Many epilepsy specialists look for drugs with consistent pharmacokinetics and relatively straightforward titration, qualities that Briviact aims to provide. The medicine's role as an adjunctive therapy means it is judged less by dramatic transformation and more by incremental, measurable reductions in seizure frequency.

Researchers have spent considerable effort quantifying those increments, tracking reductions in monthly seizure counts and changes in the proportion of patients achieving 50 percent or greater improvement. Briviact's value proposition hinges on these statistics and on its tolerability profile. Where side effects do appear, neurologists weigh them carefully against the security of better seizure control. Breathing room between episodes matters: fewer emergency room visits, less time lost to postictal confusion, and more confidence for patients considering everyday activities like commuting or social evenings.

Patient stories and expectations

If you speak with patient advocate Laura Jensen, herself living with focal seizures, she describes the first weeks on Briviact as a cautious experiment. The tablets did not feel harsh on her stomach, and she noticed no dramatic mood swings during titration. She did, however, keep a detailed seizure diary, marking each day with a simple icon. After six weeks, the pattern shifted from red marks to mostly green, not eliminating episodes but stretching the distance between them. That stretching is often what patients hope for: less fear of a sudden collapse on a crowded train or in a supermarket aisle.

Jensen also notes that her neurologist framed Briviact realistically: an attempt to improve control, not a promise of seizure freedom. This sober counselling matters, especially for young adults who may have cycled through several antiepileptics already. By aligning expectations with clinical data, physicians reduce frustration if results are modest. At the same time, they can celebrate measurable gains, like a 30 percent reduction in monthly seizures, without overhyping the medicine as a cure.

Side effects and practical trade-offs

No antiepileptic comes without trade-offs, and Briviact is no exception. Commonly discussed side effects include dizziness, fatigue and irritability, alongside potential changes in liver enzymes. Neurologists typically monitor patients through regular consultations, asking specific questions about concentration, mood and physical stamina rather than waiting for patients to volunteer complaints. This structured questioning helps catch subtle issues early, before they start to erode adherence.

From a practical household perspective, the biggest concern often lies not in one dramatic side effect but in a slow build-up of tiredness. If a parent notices that homework takes longer or that a teenager dozes off earlier in the evening, they may raise the issue with the neurologist. Dose adjustments or schedule modifications can then be considered. The goal, as Tellier repeatedly stresses in public remarks, is a consistent balance: enough seizure control to protect daily functioning, without pushing side effects into the foreground.

Market positioning and competition

Briviact lives in a crowded therapeutic landscape. Generic levetiracetam remains widely used, and newer agents continue to appear. UCB, however, leverages its long-standing relationships in epilepsy to maintain Briviact's visibility among specialists. By focusing on partial-onset seizures and adjunctive use, the company avoids direct head-to-head competition with every new entrant, instead carving out a defined niche. That niche connects closely with UCB's broader strategy of concentrating resources in neurology and immunology rather than spreading across multiple unrelated therapeutic areas.

For retail investors, this focus is significant. A product like Briviact does not dominate headlines like a blockbuster oncology drug, but it contributes to a portfolio that is relatively coherent and branded strongly within neurological care. Such coherence can be easier to analyze than a scattered product mix. It also offers potential cross-learning between compounds, as data from Briviact and levetiracetam use inform future design of CNS molecules.

Regulators, labels and safety nets

Regulatory authorities typically require robust randomized controlled trials and post-marketing surveillance to maintain a product like Briviact on the market. That means ongoing pharmacovigilance structures, often coordinated by UCB's safety teams, collect reports of adverse events from physicians and patients. These reports feed into periodic safety updates and, when necessary, label changes that refine guidance on dosing, contraindications or monitoring. For families reading the leaflet in their native language, these updates translate into concrete advice: what to watch, when to call the doctor, which other drugs may interact.

The leaflet itself is a tactile element in the treatment experience. Unfolded, it rustles and spreads across the table in dense text, yet patients often focus on a few sections: indications, dosing, side effects and what to do if a dose is missed. In the case of Briviact, clear instructions on missed doses and the danger of abrupt discontinuation help anchor daily routines. Abrupt stopping of antiepileptics can provoke seizures, so calm, explicit warnings in the leaflet work as a quiet safety net, nudging patients to consult their physician rather than improvising.

Where Briviact fits in UCB's story

Net-net, Briviact illustrates UCB's evolution from a broader pharmaceutical company to a firm sharply tuned to neurology and immunology. It may not be the largest revenue source, but it demonstrates a consistent willingness to refine mechanisms like SV2A targeting rather than abandoning them after the first successful product. That continuation can reassure neurologists, who see their daily practice supported not by one-off launches but by a sequence of related options. For patients, it signals that their therapeutic area remains on the agenda in Brussels and beyond.

UCB S.A. shares (ISIN BE0003739530) are listed on Euronext Brussels; the UCB S.A. share price in euros is closely watched by investors who track how neurology products like Briviact contribute to the company's medium-term revenue mix.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.

en | BE0003739530 | UCB | boerse | 69656324 | bgmi